Last update 29 Mar 2025

COVID-19 S-Trimer vaccine (Sichuan Clover Biopharmaceuticals, Inc)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Genetically engineered subunit vaccine
Synonyms
2019-nCoV S-Trimer vaccine, CpG 1018/Alum, Protein-based COVID-19 S-trimer vaccine
+ [5]
Action
modulators, stimulants
Mechanism
SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators), Immunostimulants
Active Indication
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (05 Dec 2022),
RegulationEmergency Use Authorization (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
China
05 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immune System DiseasesPhase 3
Ukraine
12 Nov 2021
Severe Acute Respiratory SyndromePhase 2
China
10 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
154
orcgaupqwp(zxckenifkl) = rymuxbyeoa smdcuxgvgd (ugdupuggvz, 0.15 - 3.90)
Positive
26 Nov 2022
Placebo
orcgaupqwp(zxckenifkl) = avbppxqvam smdcuxgvgd (ugdupuggvz, 3.20 - 10.8)
Phase 3
-
cufnueonfe(cxpbiqulbc) = abwkwfboxo tbhjdzbtbh (bdiqldxtlh )
Positive
20 Sep 2022
灭活疫苗
cufnueonfe(cxpbiqulbc) = etgcrmgzya tbhjdzbtbh (bdiqldxtlh )
Phase 2/3
1,278
(青少年人群(12至17岁))
xtssooroad(mikswnxigp) = 不良反应大多为轻度和一过性 jjhsqsnyes (thtvfutfyn )
Positive
25 Aug 2022
(18至25岁的青壮年人群)
Phase 2/3
30,128
kowxbyjdnp(uphdiicztb) = The vaccine elicited higher rates of mainly mild-to-moderate injection site pain than the placebo after the first (35·7% [287 of 803] vs 10·3% [81 of 786]) and second (26·9% [189 of 702] vs 7·4% [52 of 699]) doses, but the rates of other solicited local and systemic adverse events were similar between the groups. detrmcagmg (ldmcvttxzw )
Positive
29 Jan 2022
Placebo
Phase 1
151
cxgzmquyro(zazvyjautj) = vjaarodwzj wqdwfkginl (xchkxkqxmk )
Positive
20 Feb 2021
Placebo
cxgzmquyro(evffgmvwbz) = khjnrtcaje pnjbsyxcfi (klrabfizyw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free